Subscribe to our RSS feed

The Latest Health Stories

  • HIV: A gift given to me
  • Return to the scene
  • People living with HIV make their mark at IAS 2015 in Vancouver
  • Vancouver conference confirms tools are in place, shows the way to move forward to end the epidemic
  • Would you date an HIV-positive guy?

General Health

Jun05

High lifetime costs of treating HIV show importance of investing in prevention

Friday, 05 June 2015 Written by // Guest Authors - Revolving Door Categories // General Health, Research, Health, International , Treatment, Living with HIV, Revolving Door, Guest Authors

Aidsmap reports on research that says the lifetime cost for treating one HIV infection in the UK is almost £380,000

High lifetime costs of treating HIV show importance of investing in prevention

This article by Michael Carter first appeared on aidsmap.com here.  

The lifetime cost for treating one HIV infection in the UK is almost £380,000, according to a model published in the online journal PLOS One. Switching to generic drugs once patents expired could reduce costs to just over £100,000. The investigators based their calculations on costs associated with treating a 30-year-old gay man infected in 2013 who lived to the age of 72 years. It was assumed that standards of HIV treatment and care were those specified in the 2012 edition of the guidelines of the British HIV Association (BHIVA).

“If 3,000 MSM [men who have sex with men] had been infected in 2013…and all were aged 30 years at infection then the future direct lifetime costs relating to HIV care amounts to approximately £1.1 billion,” write the authors. “Even with the future use of generics, the total sum remains in excess of £0.5 billion.” The authors believe these figures show the vital importance of investing in effective prevention strategies.

Thanks to improvements in HIV treatment and care, most patients with HIV in the UK and similar countries now have an excellent life expectancy. Researchers in the UK have calculated that, even after taking into consideration an increased risk of early death due to liver, kidney and heart disease and some cancers, a 30-year-old gay man with recent HIV infection would live until the age of 72 years.

As of 2013, there were 81,500 people accessing HIV care in the UK. The good life expectancy of people with HIV and continued high rates of new diagnoses – 6500 in 2013 – means that the number of people living with HIV in the UK is likely to increase significantly in coming years.

A team of investigators wanted to estimate the likely cost implications of the ongoing high rates of HIV infections in the UK. They hoped their findings would provide “valuable insights” for the evaluation of possible prevention initiatives.

They developed a model projecting the additional lifetime healthcare costs for gay and other MSM aged 30 years and infected with HIV in 2013. The model assumed no loss to follow-up and that standards and costs of healthcare remained as now. The first calculation was based on the use of patented drugs. The authors also estimated the impact of various strategies to reduce the cost of treatment and care – frequency of follow-up visits and CD4 cell monitoring; ritonavir-boosted protease inhibitor monotherapy for virologically suppressed patients; switching to generics after the patents on branded drugs expired. The authors performed 10,000 simulations.

The estimated mean lifetime cost of treating a single person was £360,800. With annual discounting of 3.5%, the cost was reduced to £185,000.

Reduced frequency of follow-up and monitoring all achieved cost savings, but the biggest price reduction was associated with switching to generic formulations – this reduced the estimated lifetime cost by half to £179,000, and with discounting the cost fell further to just over £100,000.

“In view of the high lifetime costs for HIV-positive individuals, there is large scope for preventative interventions to be cost-effective,” conclude the authors. “Our results show that for settings with good access to cART [combination antiretroviral therapy] and HIV care, it is imperative for investment into prevention programmes to be continued or scaled-up. Further reductions in drug prices by using generic antiretroviral drugs in place of patented drugs would reduce these costs considerably.”

Reference

Nakagawa F et al. Projected lifetime healthcare costs associated with HIV infection. PLOS One 10(4): e01205018, 2015.

  • HIV: A gift given to me

    HIV: A gift given to me

    Guest writer RYU Matsumoto from The Philippines says “I know the virus isn’t something to be thankful for, but this virus taught me the life lessons I’ve started to miss.”
  • Return to the scene

    Return to the scene

    Still dealing with the aftermath of a relationship that went bad, Toronto's Josh says “I feel like there’s still a lot of work to do on my mental health. And I’m open about that, and am taking the steps I need to take to do that.”
  • People living with HIV make their mark at IAS 2015 in Vancouver

    People living with HIV make their mark at IAS 2015 in Vancouver

    Bob Leahy reports on the Canadian Declaration by Persons Living with HIV that calls for the protection of human rights in light of biomedical advances in HIV Treatment but in a progressive way supportive of 90-9-90 and expanded treatment access
  • Vancouver conference confirms tools are in place, shows the way to move forward to end the epidemic

    Vancouver conference confirms tools are in place, shows the way to move forward to end the epidemic

    Bob Leahy was in Vancouver last week for IAS 2015 for what he terms “a moment in time when the end of AIDS really does seem in sight”. Here is his very personal view of conference highlights
  • Would you date an HIV-positive guy?

    Would you date an HIV-positive guy?

    Says FS Magazine’s CEO “Avoiding sex or a relationship with someone just because they’re living with HIV isn’t a good strategy: it won’t prevent you from becoming HIV-positive . . and it contributes to an unacceptable caste system.”
  • In search of the invisible man

    In search of the invisible man

    From CATIE’s The Positve Side, “Straight men living with HIV”
  • The diagnosis [4]

    The diagnosis [4]

    Guest writer RYU Matsumoto from The Philippines with the fourth part of his story of being diagnosed with HIV. Today - on leaving hospital, returning home and finally a return to good health
  • National drug plan needed for Canada

    National drug plan needed for Canada

    We have universal healthcare that, unusual in industrialized countries, that doesn’t cover drugs. Toronto's Josh says “a national drug program would mean equal access to the life-saving drugs we need, at no cost to us.”
  • Frank talk from Julio Montaner

    Frank talk from Julio Montaner

    From IAS 2015 Bob Leahy speaks (again) with BC’s Dr. Julio Montaner, the world’s leading treatment as prevention advocate, about 90-90-90, his frustrations with uptake in Canada – and meeting the Pope.
  • HIV Happy

    HIV Happy

    Bob Leahy talks to UK writer Paul Thorn about his new book which explains how a harmonious and happy co-existence with HIV is possible and how to make the most of the second chance that treatment affords you
  • Inside look at Insite

    Inside look at Insite

    In Vancouver for IAS 2015, Bob Leahy visits Insite, the supervised injection facility in the downtown east side, where every day 800+ people with addictions and multiple other issues inject drugs in a safe, clean environment that also gives them a hand up

MarketPlace